News | September 10, 2007

Carestream Highlights New Dyes for In Vivo Imaging

September 11, 2007 - Carestream Molecular Imaging, a division of Carestream Health Inc., announced at the Joint Molecular Imaging Conference the introduction of new large Stokes shift dyes for fluorescent in vivo imaging applications, KODAK X-SIGHT Large Stokes Shift Dyes, which are reactive dyes designed to enable researchers and scientists to maximize the fluorescent signal while minimizing auto-fluorescence issues during in vivo imaging.
“Stokes shift” refers to the separation of absorption and emission maxima. Having a significantly larger Stokes shift—greater than 80 nanometers in the case of KODAK X-SIGHT Dyes—helps researchers eliminate much of the background that typically obstructs the fluorescent signal while allowing researchers to excite and emit the dyes at their maxima, thus resulting in far greater signal to noise. Most commercially available dyes typically have a Stokes shift between 20-30 nanometers.
In an organism, the KODAK X-SIGHT Dyes can illuminate a region of interest when excited by the appropriate wavelength of fluorescent light, thus allowing the researcher to visualize their target. While the KODAK X-SIGHT Imaging Agents have been optimized for KODAK Image Station and In-Vivo Systems, they are also compatible with other commercially available digital imaging systems.
“Our new KODAK X-SIGHT Large Stokes Shift Dyes, characterized by near infrared emission and a large Stokes shift, enable researchers to achieve a higher sensitivity of fluorescent detection deeper into tissue,” said Shahram Hejazi, PhD, President of Carestream Molecular Imaging. “With superior performance when compared to other commercially available products, these new dyes validate our outstanding dye chemistry expertise and leadership in fluorescent imaging.”
KODAK X-SIGHT Dyes will be available this fall for preclinical use.

For more information: www.MIStore.carestreamhealth.com and www.carestreamhealth.com

Related Content

Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...